CD47 and cancer: Moreover, as the receptor of CD47, SIRPα can also be targeted to inhibit the CD47–SIRPα pathway and recently, the monoclonal antibody KWAR23, which binds human SIRPα, given in combination with tumor-opsonizing monoclonal antibodies, greatly increased the cell-dependent killing of both hematopoietic and nonhematopoietic human cancer cell lines [31].